User:MaryGaulke/sandbox/Terren Peizer mockup

Terren Scott Peizer is an investor; financier; and founder, chairman and CEO of Ontrak. He is also chairman of the Los Angeles-based investment company Acuitas Group Holdings.

Peizer has held various senior executive positions within several technology and biotech companies. In the 1980s, he was a bond trader at Drexel Burnham Lambert.

Early life and education
Peizer was born in 1959, and raised in Beachwood, Ohio. He graduated from the Wharton School of the University of Pennsylvania.

Early career and Drexel Burnham Lambert
Peizer began his career at Goldman Sachs and First Boston. Michael Milken then hired Peizer as a bond salesman at Drexel Burnham Lambert in 1985. Peizer received a $3.5 million dollar salary, and a $500,000 loan to invest in the partnership. Peizer worked directly under (and at the same desk as) Milken, whom he admired, sometimes pretending to be him on the phone.

When investigations into Milken's illegal activities started, Peizer agreed to provide material evidence to prosecutors in exchange for immunity. Peizer later claimed he felt "compelled" to testify against Milken, although he (Peizer) was not specifically the subject of the investigation.

1989–2000
In 1989, Peizer purchased a minor league basketball team, the Omaha Racers. He sold his majority stake a year later.

Following his departure from Drexel Burnham Lambert, Peizer took on leadership roles at a series of medical and technology companies and promoted their stocks. In 1991 he became Chairman of Urethane Technologies (then UTI Chemicals), which produced bicycle tires. He exited the company in 1994; it went bankrupt in 1997.

From 1993 to 1995, Peizer was Chairman of CMS Enhancements (a subsidiary of Ameriquest), which produced computer parts. From 1997 to 1999, he was president of Hollis-Eden, a pharmaceutical company that was developing a drug to treat HIV/AIDS. In August 1999, Peizer became chairman of Tera Computer Company, a manufacturer of supercomputers. At Tera, Peizer raised funding and led the acquisition of Cray from SGI in March 2000. The merged company took the name Cray, Inc. Peizer left the chairman role at Cray in December 2000 but stayed with the company as a director.

Prometa
Peizer founded Hythiam, an addiction treatment company, in 2004. According to Peizer, he became interested in addiction treatment because of his half-brother's struggles with addiction. In 2007, 60 Minutes and The Dallas Morning News criticized Peizer after Hythiam circumvented clinical studies and government approval when bringing Prometa, a treatment program for methamphetamine addiction, to market.

In 2011, Hythiam changed its name to Catasys, retaining Peizer as chairman and CEO of the company.

2018–present
In 2018, Peizer became CEO and director of BioVie, a pharmaceutical company. In July 2020, Catasys, of which Peizer is chairman and CEO, changed its name to that of its Ontrak product.